Inicio・Lista de Acciones・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Cerrado

SectorSanidad

103.05 20.03

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

101.15

Máximo

103.27

Métricas clave
By Trading Economics
Ingresos	292M 150M
Ventas	-75M 377M
P/B Media del Sector	28.867 68.51
BPA	1.221
Margen de beneficios	39.832
Empleados	423
EBITDA	-62M 220M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	-9.09% downside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.1B 9.8B
Apertura anterior	83.02
Cierre anterior	103.05

Noticias sobre sentimiento de mercado

By Acuity

35%

65%

75 / 340 Clasificación en Healthcare

Halozyme Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2026, 23:21 UTC

News

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

6 ago 2026, 23:51 UTC

News

Social Media

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

5 ago 2026, 22:16 UTC

Halozyme Therapeutics shares are lower in after-market trading, reflecting broader market pressures amid mixed sentiment from geopolitical developments and weak employment data.

4 ago 2026, 19:22 UTC

News

Halozyme Therapeutics is higher today, driven by 39.1% revenue growth from its ENHANZE technology, which enhances market share and earnings performance.

3 ago 2026, 19:46 UTC

Halozyme Therapeutics Inc. shares are lower today, despite earlier gains, amid a broader market rally following a significant drop in oil prices.

31 jul 2026, 20:06 UTC

Shares of Halozyme Therapeutics are lower today, reflecting broader market trends amid rising U.S. Treasury yields and crude oil prices influencing inflation concerns.

30 jul 2026, 19:58 UTC

Halozyme Therapeutics Inc shares are higher, reflecting a broader recovery in technology stocks amid improved market sentiment. The stock remains near its one-month range.

29 jul 2026, 19:27 UTC

Social Media

Halozyme shares are higher today, despite earlier pulling back. Recent commentary raises concerns about future performance and potential writedowns from acquisitions.

28 jul 2026, 20:03 UTC

Halozyme Therapeutics Inc. is trading higher, benefiting from a broader upward trend in biotechnology stocks, despite a pullback earlier in the session.

27 jul 2026, 19:46 UTC

Shares of Halozyme Therapeutics Inc. are lower today, continuing a decline since Friday. Broader market sentiment is affected by a drop in crude oil prices.

24 jul 2026, 20:07 UTC

News

Halozyme Therapeutics is gaining traction as shares rise, supported by strong cash flow margins and revenue growth. The stock is currently priced at $80.60 per share.

22 jul 2026, 19:35 UTC

Halozyme Therapeutics shares are lower today, despite an earlier peak gain. The decline follows a drop since Tuesday's close amid rising crude oil prices.

Comparación entre iguales

Cambio de precio

Halozyme Therapeutics Inc previsión

Precio Objetivo

By TipRanks

-9.09% descenso

Estimación a 12 Meses

Media 93.75 USD -9.09%

Máximo 115 USD

Mínimo 57 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Halozyme Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Halozyme Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

75 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.